Skip to content

Released Mar 18, 2022, after the close

10-K filed Mar 18, 2022, 77 days after period end · 0000950170-22-004156

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$12.98MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$13,000,000N/M
Operating Cash Flowderived-$4,665,000N/M
Free Cash Flowderived-$5,442,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019
Net Income-$12.98M-$8.39M-$11.68K
EPS Diluted——$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR